156 related articles for article (PubMed ID: 36109733)
1. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data.
Stepniewska K; Allen EN; Humphreys GS; Poirot E; Craig E; Kennon K; Yilma D; Bousema T; Guerin PJ; White NJ; Price RN; Raman J; Martensson A; Mwaiswelo RO; Bancone G; Bastiaens GJH; Bjorkman A; Brown JM; D'Alessandro U; Dicko AA; El-Sayed B; Elzaki SE; Eziefula AC; Gonçalves BP; Hamid MMA; Kaneko A; Kariuki S; Khan W; Kwambai TK; Ley B; Ngasala BE; Nosten F; Okebe J; Samuels AM; Smit MR; Stone WJR; Sutanto I; Ter Kuile F; Tine RC; Tiono AB; Drakeley CJ; Gosling R; Stergachis A; Barnes KI; Chen I
BMC Med; 2022 Sep; 20(1):350. PubMed ID: 36109733
[TBL] [Abstract][Full Text] [Related]
2. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Mwaiswelo R; Ngasala BE; Jovel I; Gosling R; Premji Z; Poirot E; Mmbando BP; Björkman A; Mårtensson A
Malar J; 2016 Jun; 15():316. PubMed ID: 27287612
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.
Bancone G; Chowwiwat N; Somsakchaicharoen R; Poodpanya L; Moo PK; Gornsawun G; Kajeechiwa L; Thwin MM; Rakthinthong S; Nosten S; Thinraow S; Nyo SN; Ling CL; Wiladphaingern J; Kiricharoen NL; Moore KA; White NJ; Nosten F
PLoS One; 2016; 11(3):e0151898. PubMed ID: 27010542
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.
Raman J; Allen E; Workman L; Mabuza A; Swanepoel H; Malatje G; Frean J; Wiesner L; Barnes KI
Malar J; 2019 Jun; 18(1):209. PubMed ID: 31234865
[TBL] [Abstract][Full Text] [Related]
6. Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2014 Jun; (6):CD008152. PubMed ID: 24979199
[TBL] [Abstract][Full Text] [Related]
7. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.
Graves PM; Choi L; Gelband H; Garner P
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008152. PubMed ID: 29393511
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.
Onyamboko MA; Olupot-Olupot P; Were W; Namayanja C; Onyas P; Titin H; Baseke J; Muhindo R; Kayembe DK; Ndjowo PO; Basara BB; Okalebo CB; Williams TN; Uyoga S; Taya C; Bamisaiye A; Fanello C; Maitland K; Day NPJ; Taylor WRJ; Mukaka M
BMC Med; 2023 Oct; 21(1):397. PubMed ID: 37858129
[TBL] [Abstract][Full Text] [Related]
9. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial.
Taylor WR; Olupot-Olupot P; Onyamboko MA; Peerawaranun P; Weere W; Namayanja C; Onyas P; Titin H; Baseke J; Muhindo R; Kayembe DK; Ndjowo PO; Basara BB; Bongo GS; Okalebo CB; Abongo G; Uyoga S; Williams TN; Taya C; Dhorda M; Tarning J; Dondorp AM; Waithira N; Fanello C; Maitland K; Mukaka M; Day NJP
Lancet Infect Dis; 2023 Apr; 23(4):471-483. PubMed ID: 36462528
[TBL] [Abstract][Full Text] [Related]
10. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2015 Feb; (2):CD008152. PubMed ID: 25693791
[TBL] [Abstract][Full Text] [Related]
11. Primaquine for reducing Plasmodium falciparum transmission.
Graves PM; Gelband H; Garner P
Cochrane Database Syst Rev; 2012 Sep; (9):CD008152. PubMed ID: 22972117
[TBL] [Abstract][Full Text] [Related]
12. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Poirot E; Soble A; Ntshalintshali N; Mwandemele A; Mkhonta N; Malambe C; Vilakati S; Pan S; Darteh S; Maphalala G; Brown J; Hwang J; Pace C; Stergachis A; Vittinghoff E; Kunene S; Gosling R
Malar J; 2016 Jul; 15(1):384. PubMed ID: 27450652
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial.
Tine RC; Sylla K; Faye BT; Poirot E; Fall FB; Sow D; Wang D; Ndiaye M; Ndiaye JL; Faye B; Greenwood B; Gaye O; Milligan P
Clin Infect Dis; 2017 Aug; 65(4):535-543. PubMed ID: 28605472
[TBL] [Abstract][Full Text] [Related]
14. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
15. [Role of primaquine in malaria control and elimination in French-speaking Africa].
Briolant S; Pradines B; Basco LK
Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
[TBL] [Abstract][Full Text] [Related]
16. Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa.
van Beek SW; Svensson EM; Tiono AB; Okebe J; D'Alessandro U; Gonçalves BP; Bousema T; Drakeley C; Ter Heine R
Parasit Vectors; 2021 Oct; 14(1):524. PubMed ID: 34627346
[TBL] [Abstract][Full Text] [Related]
17. A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.
Mwaiswelo RO; Ngasala B; Msolo D; Kweka E; Mmbando BP; Mårtensson A
Malar J; 2022 Mar; 21(1):84. PubMed ID: 35279143
[TBL] [Abstract][Full Text] [Related]
18. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
[TBL] [Abstract][Full Text] [Related]
19. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
Dicko A; Brown JM; Diawara H; Baber I; Mahamar A; Soumare HM; Sanogo K; Koita F; Keita S; Traore SF; Chen I; Poirot E; Hwang J; McCulloch C; Lanke K; Pett H; Niemi M; Nosten F; Bousema T; Gosling R
Lancet Infect Dis; 2016 Jun; 16(6):674-684. PubMed ID: 26906747
[TBL] [Abstract][Full Text] [Related]
20. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Eziefula AC; Bousema T; Yeung S; Kamya M; Owaraganise A; Gabagaya G; Bradley J; Grignard L; Lanke KH; Wanzira H; Mpimbaza A; Nsobya S; White NJ; Webb EL; Staedke SG; Drakeley C
Lancet Infect Dis; 2014 Feb; 14(2):130-9. PubMed ID: 24239324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
